» Articles » PMID: 38344179

Exploration of Biomarkers for Efficacy Evaluation of Traditional Chinese Medicine Syndromes of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Based on Metabolomics

Overview
Journal Front Pharmacol
Date 2024 Feb 12
PMID 38344179
Authors
Affiliations
Soon will be listed here.
Abstract

Traditional Chinese medicine (TCM) is effective for the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD); however, there is no objective index for the evaluation of TCM syndrome efficacy. This study aimed to screen biomarkers related to the efficacy of TCM syndrome using metabolomics. We recruited AECOPD patients with phlegm-heat congesting lung (PH)/phlegm-damp amassing lung (PD) syndrome and treated them with Chinese herbal medicine (Qingre Huatan or Zaoshi Huatan granules) in addition to conventional medicine for 7 days. Data on clinical symptoms and sign scores, modified British Medical Research Council (mMRC), COPD assessment test (CAT), and inflammation indicators, including white blood cell (WBC) count, percentage of neutrophil count (NEU%), and C-reactive protein (CRP), were collected before and after treatment to evaluate the therapeutic effect. Serum samples were collected before and after treatment for metabolomic analysis to screen differential metabolites. A total of 69 patients with AECOPD were enrolled, including 41 and 28 patients in the PH and PD groups, respectively. The clinical symptoms and sign scores, CAT, mMRC, NEU%, and CRP levels after treatment were lower than those before treatment in both groups ( < 0.05). Serum metabolomics analysis showed that there were 13 differential metabolites in the PH group and 16 differential metabolites in the PD group before and after treatment ( < 0.05, variable importance projection (VIP) ≥ 1.00). In the PH group, lysophosphatidylcholine (LPC) (16:0), LPC (17:1), LPC (18:3), LPC (18:2), and LPC (17:0) negatively correlated with clinical symptoms and sign scores ( < 0.05); LPC (16:0), LPC (17:1), LPC (16:1), and LPC (17:0) negatively correlated with WBC ( < 0.05) and NEU% ( < 0.05); and LPC (16:0) negatively correlated with CRP levels. In the PD group, L-phenylalanine positively correlated with CRP levels ( < 0.05), and 2-methylbutyroylcarnitine positively correlated with clinical symptoms and sign ( < 0.05) and CAT scores ( < 0.05). DL-carnitine positively correlated with clinical symptoms and sign scores ( < 0.05). Serum metabolites may be potential indicators to objectively evaluate the efficacy of TCM syndromes; however, further large controlled trials are required to verify these findings.

Citing Articles

Dissecting causal relationships between immune cells, plasma metabolites, and COPD: a mediating Mendelian randomization study.

Cao Z, Wu T, Fang Y, Sun F, Ding H, Zhao L Front Immunol. 2024; 15:1406234.

PMID: 38868780 PMC: 11168115. DOI: 10.3389/fimmu.2024.1406234.

References
1.
Conlon T, Bartel J, Ballweg K, Gunter S, Prehn C, Krumsiek J . Metabolomics screening identifies reduced L-carnitine to be associated with progressive emphysema. Clin Sci (Lond). 2015; 130(4):273-87. DOI: 10.1042/CS20150438. View

2.
. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

3.
Piccirillo A, Hyzny E, Beppu L, Menk A, Wallace C, Hawse W . The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8 Memory T Cell Maintenance and Secondary Response to Infection. J Immunol. 2019; 203(1):117-126. PMC: 6581627. DOI: 10.4049/jimmunol.1801585. View

4.
Wang L, Tang Y, Liu S, Mao S, Ling Y, Liu D . Metabonomic profiling of serum and urine by (1)H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals. PLoS One. 2013; 8(6):e65675. PMC: 3675021. DOI: 10.1371/journal.pone.0065675. View

5.
Luo P, Yu H, Zhao X, Bao Y, Hong C, Zhang P . Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry. J Proteome Res. 2016; 15(4):1288-99. DOI: 10.1021/acs.jproteome.6b00022. View